AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

NCT02440568 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine
DRUG: Idarubicin
DRUG: Omacetaxine mepesuccinate
DRUG: Omacetaxine mepesuccinate
DRUG: Omacetaxine mepesuccinate
DRUG: Omacetaxine mepesuccinate

Sponsor

University of Illinois at Chicago

Collaborators

[object Object]